To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
1) Patients must be ≥ 16 years of age;
2) Patients receiving haploidentical allo-HSCT;
3) Patients have to sign an informed consent form before the start of the research procedure.
1) Tandem transplantation or multiple transplantations;
2) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
3) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Parallel
Health monitoring and regular return follow-up reminders
BehavioralHealth monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
Survival
Overall survival during 1.5 years after transplantation
Non-relapse mortality rate
Non-relapse mortality rate during 1.5 years after transplantation
Incidence of infections
Infections during 1.5 years after transplantation
Immune cell count
Data on immune cell count will be collected during 1.5 years after transplantation
Click on the lead sponsor to view all of their trials.
